Royalty Pharma

Unternehmensprofil

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Beschreibung auf Englisch verfügbar.

Unternehmensdaten

Branche

Gesundheit

Industrie

Biotechnology

Land

Vereinigte Staaten

Hauptsitz

110 East 59th Street, 10022, New York

Mitarbeitende

100

Notierung

RPRX · NASDAQ

Währung

USD

Website

royaltypharma.com